{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T05:22:16Z","timestamp":1778044936849,"version":"3.51.4"},"reference-count":19,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T00:00:00Z","timestamp":1725753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>The use of partial residual plots (PRPs) was explored as a model diagnostic tool in Model\u2010based Meta\u2010Analysis (MBMA). Mathematical derivations illustrating the concepts were followed by an MBMA example using publicly available literature data of anti\u2010depressive treatments with fluoxetine and venlafaxine. An <jats:italic>E<\/jats:italic><jats:sub>max<\/jats:sub> dose\u2013response model was identified for venlafaxine while a constant drug effect combining all dose levels vs. placebo was identified for fluoxetine. The larger the mean baseline Hamilton Depression Rating (HAMD) score, the larger the expected drug effect (<jats:italic>P<\/jats:italic>\u2009=\u20090.0122), based on the likelihood ratio test. Mean baseline HAMD score (range) was 25.4 (23.5, 29.4) and 20.8 (15, 26) while mean placebo change from baseline (range) was \u22129.02 (\u221212.2, \u22124.8) and\u2009\u2212\u20096.22 (\u221210.9, \u22121.3) for venlafaxine and fluoxetine, respectively. Average baseline HAMD score appeared larger for venlafaxine compared to fluoxetine, albeit a wider range for fluoxetine. Placebo response seemed lower but also more variable in fluoxetine compared to venlafaxine studies. Observed data points tended to deviate from model predictions when the mean baseline HAMD and placebo response values associated with those data points differed substantially from the corresponding values used for the model prediction. Normalizing observed data addressed this, providing a \u201clike\u2010to\u2010like\u201d comparison with model predictions in PRP when assessing the effect of one covariate (dose) after normalizing for other covariates\/effects (placebo response and mean baseline). PRPs provide a robust integrated diagnostic tool in MBMA that uses all data to show the correlation between response and any covariate while controlling for other covariates included in the model.<\/jats:p>","DOI":"10.1002\/cpt.3418","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T04:39:49Z","timestamp":1725856789000},"page":"153-161","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Partial Residual Plots as an Integrated Model Diagnostic Tool in Model\u2010Based Meta\u2010Analysis"],"prefix":"10.1002","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5423-0800","authenticated-orcid":false,"given":"John","family":"Maringwa","sequence":"first","affiliation":[{"name":"Clinical Pharmacology and Pharmacometrics Janssen\u2010Cilag BV  Breda The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3567-7903","authenticated-orcid":false,"given":"Paul Matthias","family":"Diderichsen","sequence":"additional","affiliation":[{"name":"Certara USA Inc  Radnor Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandni","family":"Valiathan","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Pharmacometrics Janssen Research &amp; Development LLC  La Jolla California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,9,8]]},"reference":[{"key":"e_1_2_11_1_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-022-03201-5"},{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2004.00939.x"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2012.23"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.732"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.256"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.242"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-001844"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2014.11.008"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01793-21"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1624"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4612-4444-8_1"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781118625590"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2130"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-011-9255-z"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12679"},{"key":"e_1_2_11_16_1","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/draft\u2010guideline\u2010clinical\u2010investigation\u2010medicinal\u2010products\u2010treatment\u2010depression\u2010revision\u20103_en.pdf."},{"key":"e_1_2_11_17_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2","author":"Higgins J.P.T.","year":"2009"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.32614\/RJ-2017-010"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.3418","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T06:00:16Z","timestamp":1734501616000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.3418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,8]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1002\/cpt.3418"],"URL":"https:\/\/doi.org\/10.1002\/cpt.3418","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,8]]},"assertion":[{"value":"2024-02-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}